Smith & Nephew plc (SN.L) Stock Analysis

Free AI-powered analysis and research for Smith & Nephew plc stock

Sector: Healthcare

SN.L snapshot

Data as of 4 Nov 2026 close. Updated daily.

Last close

1,190.00 GBX (+6.49%)

52-week range

980.40 – 1,426.59

Position in range

47%

1-year change

-16.0%

Market cap (USD)

$13.4B

P/E (trailing)

20.4

RSI (14-day)

vs 200-day average

+3.3%

MACD

Above signal line

StockIQ score: 85/100 · Strongly positive signals

Smith & Nephew plc scores 85/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 47% of its 52-week range, down 16.0% over the past year. Latest reported figures show a profit margin of 10.1%, return on equity of 11.9% and revenue growth of +4.6%.

What is driving the score

Strong Uptrend: +12
MACD Bullish: +8
Good Profit Margin (10.1%): +5
Strong Liquidity (2.14 Current Ratio): +8
Above MA200: +4
Underperforming (-16.0% over 1 year): -5
High Volume (1.9x): +3

Automated, general information only – not financial advice. Scores can be wrong. How the score works

Full SN.L report

Smith & Nephew plc (SN.L) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.

Analyze SN.L Now →

People also watch

PFE

Pfizer Inc.

ISRG

Intuitive Surgical Inc.

CVS

CVS Health Corporation

PRAX

Praxis Precision Medicines, Inc.

PGEN

Precigen, Inc.